Working to provide information, support and access to established, new or innovative treatments for Atrial Fibrillation (AF)
Biosense Webster launches report - The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe
19 November 2018
Brussels, Belgium – 19 November, 2018 – Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF) has today, during AF Association Global AF Aware Week, published a report that uncovers the growing burden of AF on patients, caregivers and healthcare systems across Europe.
Download full press release here.
Download full Burden of AF report here.
Download Burden on AF Infographic here.
.png)
.svg.png)
